Table I.

Deuteporfin levels in blood and tissues of Sprague-Dawley rats following intravenous administration.

A, Following intravenous administration of deuteporfin
	Concentration of deuteporfin, µg/1
Time, h	Blood	Heart	Liver	Spleen	Lung	Kidney	Pancreas	Lymph nodes	Skin
1	108.31±1.02	13.01±2.10	75.18±3.57	0.36±0.57	1.89±2.48	58.52±5.19	30.14±2.56	28.95±7.18	26.87±0.51
3	103.00±1.14	6.76±4.11	60.47±6.21	0.33±0.52	1.18±0.46	35.47±11.83	25.89±2.29	22.87±4.42	28.08±6.37
6	37.67±0.55	6.15±1.96	60.93±7.01	0.06±0.11	1.19±1.55	31.34±13.15	30.38±4.05	25.89±5.82	32.24±4.95
12	30.00±0.27	4.95±0.83	50.11±4.5	0.02±0.05	0.86±0.23	44.43±9.34	31.60±2.85	24.78±7.26	23.74±1.50
24	26.5±0.51	3.16±0.33	47.19±10.89	0.03±0.07	0.85±1.29	52.80±11.28	30.97±0.86	16.57±2.19	25.76±5.04
48	24.18±0.07	3.03±0.25	35.29±7.05	0.02±0.06	0.81±0.69	42.51±7.09	31.95±7.93	22.47±1.72	30.86±8.29
B, Following left rear footpad administration of deuteporfin
	Concentration of deuteporfin, µg/1
Time, h	Blood	Heart	Liver	Spleen	Lung	Kidney	Pancreas	Lymph nodes	Skin
1	38.29±1.86	8.37±2.83	64.62±13.96	1.11±1.42	2.93±0.88	39.64±16.26	36.45±4.29	16.50±1.17	30.57±2.64
3	73.26±2.87	6.46±1.44	66.81±3.01	0.60±0.17	2.52±1.63	82.25±15.60	31.88±1.29	71.75±15.68	29.75±1.09
6	35.42±5.78	5.61±4.35	48.52±3.58	0.60±0.11	1.10±0.84	46.47±13.39	30.08±1.95	32.11±3.60	30.88±1.85
12	30.21±4.23	4.28±3.54	44.90±10.44	0.49±0.58	1.36±1.01	42.44±8.73	31.18±4.67	24.39±16.11	33.87±6.23
24	20.28±3.65	4.63±3.50	37.07±5.64	0.28±0.31	0.99±1.08	36.06±6.84	21.00±9.09	18.05±3.59	24.96±2.50
48	19.43±2.51	4.25±0.95	39.20±6.55	0.27±0.42	0.03±0.05	27.95±9.82	30.00±8.73	21.86±3.08	27.69±2.23

Dose of deuteporfin administered was 2.5 mg/ml. Data are expressed mean ± standard deviation, n=6.